Sydney—May 11, 2026, 08:02 AEST
Cochlear Limited will kick off trading Monday close to A$100 per share, a figure that’s become something of a litmus test for sentiment after a bruising profit warning and steep drop last month. According to MarketScreener, shares finished May 8 at A$99.89, gaining 1.7% on the session, but even after that bounce, the stock remains down 61.7% for the year.
At 08:02 AEST, the ASX cash market was sitting in its pre-open phase—brokers lining up orders, but no trades going through yet. Regular trading kicks off at roughly 09:59:45 in Sydney, so Cochlear’s opening trade typically lands under the microscope right away.
This is hardly ideal timing. According to Reuters, the S&P/ASX 200 ended Friday 1.5% lower at 8,744.40, hit by fresh Middle East tensions that sapped risk appetite. Companies with vulnerable earnings forecasts bore the brunt as investors grew less patient.
Cochlear has reduced its FY26 underlying net profit forecast to between A$290 million and A$330 million. That figure excludes certain one-off or non-recurring items. The company now expects second-half sales growth of just 2%-6% at constant currency, citing softer implant demand in developed markets, limits on hospital capacity, fewer referrals from hearing-aid channels, risks tied to Middle East deliveries and orders, plus a stronger Australian dollar. Chief Executive Dig Howitt said Cochlear must “medicalise hearing loss” so that treating adults and seniors becomes a health priority. Cochlear Assets
Just two months after steering investors to the lower end of a A$435 million to A$460 million range in February, Cochlear slashed its outlook. On April 22, the stock plunged 40.7%, closing at A$99.58—a single-day loss not seen since March 2016. The revised midpoint landed well below Visible Alpha’s A$402.5 million consensus, Reuters reported.
Analysts didn’t mince words. Steve Wheen at Jarden described the downgrade as “far worse than anticipated,” flagging worries about shaky forecasts. Sacha Krien, E&P analyst, pointed to slumping implant volumes in developed markets, unpredictable demand in emerging ones, tighter margins, and restructuring headaches. Anna Milne from Wilson Asset Management added that any lift in valuation depends on clear signs of demand turning around. Wilson Asset Management
The worry: this might be more than a blip from delayed surgeries. Morningstar’s Shane Ponraj slashed Cochlear’s fair value estimate by 51%, landing at A$110, and called the challenges structural. His note now projects average revenue and underlying profit for the next decade down 14% and 35%, respectively, pointing to U.S. cost pressures and hospital capacity bottlenecks in Europe.
Cochlear’s warning didn’t just weigh on one ASX name. Sonova, Demant, and Amplifon also declined, Finwire reported, with those hearing-health firms facing similar North American exposure.
Cochlear’s reach remains broad. In its HY26 update, the Sydney-based group reported sales spanning over 180 countries, a workforce topping 5,500, and more than 750,000 people helped to hear through its implantable devices. Still, the company puts the uptake below 5% among people globally who might benefit from such hearing solutions.
Monday brings a more focused challenge: Can Cochlear stay near that A$100 mark from Friday as investors look for signs that adult and senior implant demand has stabilized—not just cost reductions?
